Table 4.
Costs and cost-effectiveness analysis for two screening strategies: IGRA only (arm 1) and sequential screening with TST followed by IGRA (arm 2).
| Cost per Unit | Arm 1 (IGRA) |
Arm 2 (TST + IGRA) |
||||
|---|---|---|---|---|---|---|
| N. | Costs (€) | N. | Costs (€) | |||
| TST * | - | 237 | 1374.60 | |||
| IGRA | 358 | 18,705.50 | 130 | 6792.50 | ||
| Chest X-ray # | 162 | 2818.80 | 81 | 1409.40 | ||
| VE (performed as distinct from VT) | 40 | 900.00 | 26 | 585.00 | ||
| VT (performed as distinct from VE) | 28 | 630.00 | 20 | 450.00 | ||
| VE + VT (performed at a single time point) | 37 | 832.50 | 32 | 720.00 | ||
| Blood tests | 65 | 2905.50 | 52 | 2324.40 | ||
| Total | 26,792.30 | 13,655.90 | ||||
| Costs per subject undergoing TBI screening | 74.84 | 57.62 | ||||
| Costs for 100 subjects undergoing TBI screening | 7483.88 | 5761.98 | ||||
| ACER § | 412.19 | 262.61 | ||||
* Costs for TST included both costs for intradermal injection and evaluation after 48–72 h. # Chest X-ray performed for suspect active TB (in addition to those performed as part of TB infection screening): 61 for arm 1 and 11 for arm 2. § ACER (average cost-effectiveness ratio) was calculated as the ratio between the costs and the number of subjects who started treatment for each arm (65 for arm 1 and 52 for arm 2, respectively).